Votrient(pazopanib)
Pazopanib, Votrient (pazopanib) is a small molecule pharmaceutical. Pazopanib was first approved as Votrient on 2009-10-19. It is used to treat renal cell carcinoma and soft tissue neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3, vascular endothelial growth factor receptor 1, and vascular endothelial growth factor receptor 2. In addition, it is known to target platelet-derived growth factor receptor beta, fibroblast growth factor receptor 1, mast/stem cell growth factor receptor Kit, and macrophage colony-stimulating factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Pazopanib, Votrient (discontinued: Votrient)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| renal cell carcinoma | EFO_0000376 | D002292 | — |
| soft tissue neoplasms | — | D012983 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
295 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 20 | 32 | 10 | 5 | 26 | 91 |
| Carcinoma | D002277 | — | C80.0 | 15 | 37 | 10 | 4 | 17 | 80 |
| Neoplasms | D009369 | — | C80 | 30 | 11 | 2 | 1 | 5 | 44 |
| Sarcoma | D012509 | — | — | 15 | 24 | 5 | 1 | 3 | 40 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 7 | 14 | 1 | 1 | — | 18 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 8 | — | 1 | — | 17 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 3 | — | 1 | 1 | 7 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 13 | 1 | — | — | 16 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 10 | 1 | — | — | 15 |
| Leiomyosarcoma | D007890 | — | — | 2 | 8 | 2 | — | — | 8 |
| Liposarcoma | D008080 | — | — | 1 | 6 | 1 | — | — | 6 |
| Osteosarcoma | D012516 | — | — | 1 | 4 | 1 | — | — | 5 |
| Chondrosarcoma | D002813 | — | — | — | 4 | 1 | — | — | 4 |
| Neurofibrosarcoma | D018319 | — | — | 2 | 4 | 1 | — | — | 4 |
| Malignant fibrous histiocytoma | D051677 | — | — | 2 | 4 | 1 | — | — | 4 |
| Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 2 | 4 | 1 | — | — | 4 |
| Hemangiosarcoma | D006394 | — | — | — | 3 | 1 | — | — | 4 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 3 | 6 | — | — | 9 | 18 |
| Recurrence | D012008 | — | — | 2 | 9 | — | — | 1 | 11 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 4 | 9 | — | — | — | 10 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 5 | 4 | — | — | — | 9 |
| Melanoma | D008545 | — | — | 2 | 5 | — | — | — | 7 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 5 | — | — | — | 7 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 6 | — | — | — | 6 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 2 | 3 | — | — | 1 | 6 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 4 | — | — | — | 6 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 4 | — | — | — | 5 |
Show 80 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | — | — | — | 2 | 5 |
| Colorectal neoplasms | D015179 | — | — | 3 | — | — | — | — | 3 |
| Head and neck neoplasms | D006258 | — | — | 2 | — | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | — | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | — | — | — | 2 |
| Digestive system neoplasms | D004067 | — | — | 1 | — | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Thoracic neoplasms | D013899 | — | — | 1 | — | — | — | — | 1 |
| Papillary thyroid cancer | D000077273 | — | — | 1 | — | — | — | — | 1 |
| Follicular adenocarcinoma | D018263 | — | — | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | — | — | — | 1 | 1 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
| Torsades de pointes | D016171 | EFO_0005307 | I47.21 | — | — | — | — | 1 | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pazopanib |
| INN | pazopanib |
| Description | Pazopanib hydrochloride is a hydrochloride salt prepared from equimolar amounts of pazopanib and hydrochloric acid. Used for treatment of kidney cancer. It has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, a tyrosine kinase inhibitor and an angiogenesis modulating agent. It contains a pazopanib(1+). |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 444731-52-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL477772 |
| ChEBI ID | 71219 |
| PubChem CID | 11525740 |
| DrugBank | DB06589 |
| UNII ID | 7RN5DR86CK (ChemIDplus, GSRS) |
Target
Agency Approved
FLT4
FLT4
FLT1
FLT1
KDR
KDR
Organism
Homo sapiens
Gene name
FLT4
Gene synonyms
VEGFR3
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 3
Protein synonyms
Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, fms related tyrosine kinase 4, Fms-like tyrosine kinase 4, primary congenital lymphedema, Tyrosine-protein kinase receptor FLT4, VEGF receptor-3
Uniprot ID
Mouse ortholog
Flt4 (14257)
vascular endothelial growth factor receptor 3 (P35917)
Alternate
PDGFRB
PDGFRB
FGFR1
FGFR1
KIT
KIT
CSF1R
CSF1R
Organism
Homo sapiens
Gene name
PDGFRB
Gene synonyms
PDGFR, PDGFR1
NCBI Gene ID
Protein name
platelet-derived growth factor receptor beta
Protein synonyms
Activated tyrosine kinase PDGFRB, Beta platelet-derived growth factor receptor, Beta-type platelet-derived growth factor receptor, CD140 antigen-like family member B, CD140b, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-1, PDGFR-beta, Platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Pdgfrb (18596)
platelet-derived growth factor receptor beta (P05622)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Votrient – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,801 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pazopanib, Votrient
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
26,831 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use